

## Media release

### **Straumann acquires all outstanding shares in Biora**

**Basel/Malmö, 22 June 2006:** Straumann, a global leader in implant dentistry and oral tissue regeneration, announced today that it had completed the purchase of all outstanding shares in Biora AB, the Swedish biologics company acquired by Straumann through a friendly takeover in 2003. Following successful arbitration with the minor shareholders, Straumann purchased the outstanding shares for SEK 17 per share (the price paid in the original offer in 2003) plus interest as from June 2003. The outstanding shares represent 5.6% of the overall share capital of Biora AB and the amount paid, including interest, totaled SEK 25.7 million (CHF 4.3 million).

Through the acquisition Straumann considerably strengthened its competence in biologics and has built a strong global presence in oral tissue regeneration with products such as Straumann® Emdogain and Straumann® BoneCeramic.

Straumann Emdogain is a well documented easy-to-apply gel that supports the regeneration of periodontal tissues and bone. It thus helps to preserve teeth in the treatment of periodontal disease. Straumann BoneCeramic is a fully synthetic bone-graft substitute used, for example, in patients who do not have sufficient bone to support implant procedures.

Preparations are underway to launch a combination of Straumann BoneCeramic and Straumann Emdogain called 'Straumann® Emdogain PLUS', which provides combined tissue support and regenerative properties. The product together with latest clinical findings will be presented at the Europeo meeting in Madrid at the end of this month.

---

**Straumann Holding AG**, Peter Merian-Weg 12, 4002 Basel, Switzerland

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

E-mail: [corporate.communication@straumann.com](mailto:corporate.communication@straumann.com)

Homepage: [www.straumann.com](http://www.straumann.com)

#### **Contact:**

Mark Hill, Corporate Communication

+41 (0)61 965 13 21

#### **Concerning forward-looking statements**

This media release contains certain "forward-looking statements", which can be identified by the use of terminology such as "support", "preserve", "preparations", "underway", "provides", and "will", or similar wording. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group ("Group") to differ materially from those expressed or implied. These include risks related to the success of and demand for the Group's products, the potential for the Group's products to become obsolete, the Group's ability to defend its intellectual property, the Group's ability to develop and commercialize new products in a timely manner, the dynamic and competitive

environment in which the Group operates, the regulatory environment, changes in currency exchange rates, the Group's ability to generate revenues and profitability, the Group's ability to realize expansion projects or projects to establish subsidiaries in a timely manner, and the Group's ability to recruit and retain key employees. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise.

#### **About Straumann**

Headquartered in Basel, Switzerland, the Straumann Group (SWX: STMN) is a global leader in implant dentistry and oral tissue regeneration. In collaboration with the International Team for Implantology (ITI), leading clinics, research institutes and universities, the Group researches and develops implants, instruments and tissue regeneration products for use in tooth replacement solutions or to prevent tooth loss. The Group manufactures implant system components and instruments in Switzerland and the US and dental tissue regeneration products in Sweden. Straumann also offers comprehensive training and services to the dental profession worldwide. Altogether, Straumann employs approximately 1420 people worldwide and its products and services are available in more than 60 countries through the Group's 18 distribution subsidiaries and broad network of distribution partners.